Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Evercore ISI upgraded shares of TXNM Energy (NYSE:TXNM – Free Report) from an in-line rating to an outperform rating in a ...

Mark Mahaney, Evercore ISI Head of Internet Research, joins 'Closing Bell Overtime' to talk Airbnb and Roku earnings.

Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...

Five-star-rated analyst Mark Mahaney at Evercore ISI has downgraded his rating from Buy to Hold on The Trade Desk (TTD) after ...

VillageMD, the health care clinic chain backed by Walgreens Boots Alliance Inc., is working with Evercore Inc. for assistance ...

The assets are SBB doo Belgrade, NetTV Plus business and its sports broadcasting rights for the Western Balkans.

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...

Zurn Elkay has filed a registration statement (including a base prospectus) on Form S-3 and a preliminary prospectus supplement with the Securities and Exchange Commission (the “SEC”) for the offering ...